Geron Corp. (GERN)

1.41
NASDAQ : Health Technology
Prev Close 1.39
Day Low/High 1.37 / 1.42
52 Wk Low/High 0.95 / 6.99
Avg Volume 1.66M
Exchange NASDAQ
Shares Outstanding 188.42M
Market Cap 261.91M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Geron Corporation Announces Closing Of Its Public Offering Of Common Stock

Geron Corporation Announces Closing Of Its Public Offering Of Common Stock

Geron Corporation (Nasdaq: GERN) announced today the closing of its previously announced public offering of 17,391,305 shares of its common stock, as well as 2,608,695 additional shares of its common stock pursuant to...

Bernstein Liebhard LLP Announces Investigation Of Geron Corporation

Bernstein Liebhard LLP Announces Investigation Of Geron Corporation

Bernstein Liebhard LLP has commenced an investigation into possible violations of the law by certain officers and directors of Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN).

Geron Corporation Announces Full Exercise Of Over-Allotment Option

Geron Corporation Announces Full Exercise Of Over-Allotment Option

Geron Corporation (Nasdaq: GERN) announced today that, in connection with its previously announced public offering, the underwriters have exercised in full their option to purchase 2,608,695 additional shares of the...

Geron Corporation Announces The Pricing Of Its Public Offering Of Common Stock

Geron Corporation Announces The Pricing Of Its Public Offering Of Common Stock

Geron Corporation (Nasdaq:GERN) today announced the pricing of an underwritten public offering of 17,391,305 shares of its common stock at a price to the public of $5.

Citigroup, Geron: After-Hours Trading

Citigroup, Geron: After-Hours Trading

Citigroup, Geron Corp., Spectrum Pharmaceuticals and Abiomed were big movers in after-hours action on Monday.

Geron Corporation Announces Proposed Public Offering Of Common Stock

Geron Corporation Announces Proposed Public Offering Of Common Stock

Geron Corporation (Nasdaq: GERN) today announced that it is offering to sell shares of its common stock in an underwritten public offering.

Geron Expands Clinical Oncology Pipeline With License And Collaboration Agreements With Angiochem

Geron Expands Clinical Oncology Pipeline With License And Collaboration Agreements With Angiochem

Geron Corporation (Nasdaq:GERN) today announced an agreement with Angiochem, Inc.

Geron Presents Clinical Data On Its Telomerase Vaccine At The 2010 American Society Of Hematology Meeting

Geron Presents Clinical Data On Its Telomerase Vaccine At The 2010 American Society Of Hematology Meeting

Geron Corporation (NASDAQ:GERN) today announced the presentation of final data from its Phase 2 clinical trial of GRNVAC1, an autologous dendritic cell vaccine targeting telomerase, in patients with acute myelogenous...

Geron Initiates Randomized Phase 2 Clinical Trial Of Imetelstat In Breast Cancer

Geron Initiates Randomized Phase 2 Clinical Trial Of Imetelstat In Breast Cancer

Geron Corporation (Nasdaq:GERN) today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or...

Lessons From A Losing Biotech Portfolio

Lessons From A Losing Biotech Portfolio

The BSMRP, a portfolio of biotech and drug stocks chosen by readers of my weekly Mailbag, is down 13% this year.

Geron Announces Two Publications Demonstrating That Its Telomerase Inhibitor Drug Targets Cancer Stem Cells

Geron Announces Two Publications Demonstrating That Its Telomerase Inhibitor Drug Targets Cancer Stem Cells

Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data demonstrating that the company’s telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, targets...

Geron Awarded Grants Under Qualifying Therapeutic Discovery Project Program

Geron Corporation (Nasdaq:GERN) today announced that the company has been awarded $1.

Geron CEO Discusses Q3 2010 Results - Earnings Call Transcript

Geron CEO Discusses Q3 2010 Results - Earnings Call Transcript

Geron Corporation Reports 2010 Third Quarter Financial Results And Events

Geron Corporation Reports 2010 Third Quarter Financial Results And Events

Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2010.

Geron Announces Conference Call To Discuss Financial Results For The 2010 Third Quarter

Geron Corporation (Nasdaq:GERN) will announce its financial results for the 2010 third quarter on Thursday, October 28, 2010, after the closing of the equity market.

Biotech Winners & Losers: Geron, Jazz Pharma

Stem-cell outfit Geron falls and Jazz Pharmaceuticals continues to rebound Thursday in a quiet session for biotech.

Biotech Winners: King Pharmaceuticals, Pain Therapeutics

Painkillers are in the biotech spotlight Tuesday, as King Pharmaceuticals sells itself to Pfizer and tiny pain medicine developer Pain Therapeutics benefits by extension.

Biotech Winners & Losers: Alexza, Geron

Biotech Winners & Losers: Alexza, Geron

Alexza shares crash Monday after the FDA denies approval of a key drug, but Geron gains as the company begins a historic stem-cell study.

Geron Initiates Clinical Trial Of Human Embryonic Stem Cell-Based Therapy In Patients With Spinal Cord Injury

Geron Initiates Clinical Trial Of Human Embryonic Stem Cell-Based Therapy In Patients With Spinal Cord Injury

Geron Corporation (Nasdaq: GERN) today announced the enrollment of the first patient in the company’s clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1.

Geron Announces Launch Of GE Healthcare’s Human Cardiomyocyte Product For Drug Discovery And Toxicity Screening

Geron Corporation (NASDAQ:GERN) today announced that GE Healthcare has launched the first human cellular assay product for use in drug discovery and toxicity screening, developed under a license and alliance agreement...

SMSC Shares Slump in Extended Trading

Shares of SMSC fell in afterhours action as the chip maker's outlook gave investors pause.

Oliver Stone Discusses 'Money Never Sleeps'

Oliver Stone Discusses 'Money Never Sleeps'

The director of the sequel to Wall Street, which opens in theaters nationwide Friday evening, talks to TheStreet about the movie's parallels to the 2008 financial crisis.

Geron Announces Collaboration With University Campus Suffolk To Develop Human Embryonic Stem Cell-Derived Chondrocytes For Cartilage Repair

Geron Corporation (Nasdaq:GERN) today announced that the company has entered into a collaboration with University Campus Suffolk (UCS) in the U.

Geron Obtains Exclusive License For Deriving Cartilage From Human Embryonic Stem Cells From University Of Edinburgh

Geron Corporation (Nasdaq:GERN) today announced that it has entered into a worldwide, exclusive license agreement with the University of Edinburgh covering technology that allows the efficient production of ...

Santarus, Geron: Volume Movers

Several stocks trading below $5, including Santarus, were poised to move on above-average volume Thursday.

Geron Corporation To Present At Three Upcoming Investor Conferences

Geron Corporation To Present At Three Upcoming Investor Conferences

Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.

Geron Corporation Q2 2010 Earnings Call Transcript

Geron Corporation Q2 2010 Earnings Call Transcript

Geron To Proceed With First Human Clinical Trial Of Embryonic Stem Cell-Based Therapy

Geron Corporation (Nasdaq:GERN) announced today that the U.S.

Geron Corporation Reports 2010 Second Quarter Financial Results And Events

Geron Corporation (Nasdaq:GERN) today reported financial results for the three and six months ended June 30, 2010.

Geron Announces Conference Call To Discuss Financial Results For The 2010 Second Quarter

Geron Corporation (NASDAQ:GERN) will announce its financial results for the 2010 second quarter on Thursday, July 29, 2010, after the closing of the equity market.

TheStreet Quant Rating: D (Sell)